• Je něco špatně v tomto záznamu ?

PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia

Y. Zhang, Y. Gao, H. Zhang, J. Zhang, F. He, A. Hnízda, M. Qian, X. Liu, Y. Gocho, CH. Pui, T. Cheng, Q. Wang, JJ. Yang, X. Zhu, X. Liu,

. 2018 ; 131 (20) : 2256-2261. [pub] 20180206

Jazyk angličtina Země Spojené státy americké

Typ dokumentu kazuistiky, časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028578

Grantová podpora
P30 CA021765 NCI NIH HHS - United States
P50 GM115279 NIGMS NIH HHS - United States

Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) comprises ∼10% to 15% of childhood ALL cases, many of which respond exquisitely to tyrosine kinase inhibitors (TKIs), for example, imatinib in PDGFRB-rearranged ALL. However, some cases developed drug resistance to TKIs and the mechanisms are poorly understood. In this study, we identified a novel PDGFRB fusion gene, namely AGGF1-PDGFRB, and functionally characterized its oncogenic potential in vitro. Further genomic profiling of longitudinally collected samples during treatment revealed the emergence of a mutation, PDGFRBC843G , which directly conferred resistance to all generations of ABL TKIs, including imatinib, dasatinib, nilotinib, and ponatinib. PDGFRB-mutant leukemia cells are highly sensitive to multitarget kinase inhibitor CHZ868, suggesting potential therapeutic options for some patients resistant to ABL TKIs. In summary, we describe a complex clonal evolution pattern in Ph-like ALL and identified a novel PDGFRB point mutation that drives leukemia relapse after ABL TKI treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028578
003      
CZ-PrNML
005      
20190819121609.0
007      
ta
008      
190813s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood-2017-11-817510 $2 doi
035    __
$a (PubMed)29434033
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zhang, Yingchi $u State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
245    10
$a PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia / $c Y. Zhang, Y. Gao, H. Zhang, J. Zhang, F. He, A. Hnízda, M. Qian, X. Liu, Y. Gocho, CH. Pui, T. Cheng, Q. Wang, JJ. Yang, X. Zhu, X. Liu,
520    9_
$a Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) comprises ∼10% to 15% of childhood ALL cases, many of which respond exquisitely to tyrosine kinase inhibitors (TKIs), for example, imatinib in PDGFRB-rearranged ALL. However, some cases developed drug resistance to TKIs and the mechanisms are poorly understood. In this study, we identified a novel PDGFRB fusion gene, namely AGGF1-PDGFRB, and functionally characterized its oncogenic potential in vitro. Further genomic profiling of longitudinally collected samples during treatment revealed the emergence of a mutation, PDGFRBC843G , which directly conferred resistance to all generations of ABL TKIs, including imatinib, dasatinib, nilotinib, and ponatinib. PDGFRB-mutant leukemia cells are highly sensitive to multitarget kinase inhibitor CHZ868, suggesting potential therapeutic options for some patients resistant to ABL TKIs. In summary, we describe a complex clonal evolution pattern in Ph-like ALL and identified a novel PDGFRB point mutation that drives leukemia relapse after ABL TKI treatment.
650    _2
$a angiogenní proteiny $x genetika $7 D042501
650    _2
$a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a předškolní dítě $7 D002675
650    _2
$a chemorezistence $x genetika $7 D019008
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a mutace $7 D009154
650    _2
$a fúzní onkogenní proteiny $7 D015514
650    _2
$a akutní lymfatická leukemie $x farmakoterapie $x genetika $x metabolismus $x patologie $7 D054198
650    _2
$a inhibitory proteinkinas $x farmakologie $x terapeutické užití $7 D047428
650    _2
$a růstový faktor odvozený z trombocytů - receptor beta $x genetika $7 D020797
650    _2
$a recidiva $7 D012008
650    _2
$a výsledek terapie $7 D016896
650    _2
$a sekvenování celého genomu $7 D000073336
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Gao, Yufeng $u Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China. University of Chinese Academy of Sciences, Beijing, China.
700    1_
$a Zhang, Hui $u Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN. Department of Hematology and Oncology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
700    1_
$a Zhang, Jingliao $u State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. Division of Pediatric Blood Diseases Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. Center for Stem Cell Medicine, Chinese Academy of Medical Sciences, Beijing, China.
700    1_
$a He, Fuhong $u Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China. University of Chinese Academy of Sciences, Beijing, China.
700    1_
$a Hnízda, Aleš $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic; and.
700    1_
$a Qian, Maoxiang $u Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
700    1_
$a Liu, Xiaoming $u State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. Division of Pediatric Blood Diseases Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. Center for Stem Cell Medicine, Chinese Academy of Medical Sciences, Beijing, China.
700    1_
$a Gocho, Yoshihiro $u Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
700    1_
$a Pui, Ching-Hon $u Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
700    1_
$a Cheng, Tao $u State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. Division of Pediatric Blood Diseases Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. Center for Stem Cell Medicine, Chinese Academy of Medical Sciences, Beijing, China.
700    1_
$a Wang, Qianfei $u Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China. University of Chinese Academy of Sciences, Beijing, China.
700    1_
$a Yang, Jun J $u Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN. Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
700    1_
$a Zhu, Xiaofan $u State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. Division of Pediatric Blood Diseases Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. Center for Stem Cell Medicine, Chinese Academy of Medical Sciences, Beijing, China.
700    1_
$a Liu, Xin $u Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China. University of Chinese Academy of Sciences, Beijing, China.
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 131, č. 20 (2018), s. 2256-2261
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29434033 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190819121843 $b ABA008
999    __
$a ok $b bmc $g 1433727 $s 1067038
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 131 $c 20 $d 2256-2261 $e 20180206 $i 1528-0020 $m Blood $n Blood $x MED00000807
GRA    __
$a P30 CA021765 $p NCI NIH HHS $2 United States
GRA    __
$a P50 GM115279 $p NIGMS NIH HHS $2 United States
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

    Možnosti archivace